West Receives FDA 510(k) Clearance for Vial2Bag Advanced® 13mm Admixture Device
04 Dec 2023
West expands administration systems portfolio with new smaller size needle-free admixture device for immediate use IV drug transfer designed to maximize the benefits of point-of-care nursing.
EXTON, Pa., Dec. 4, 2023 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST), a global leader in innovative solutions for injectable drug administration systems, today announced FDA 510(k) clearance and launch of its Vial2Bag Advanced® 13mm admixture device.
Continue Reading
Preview
Source: PRNewswire
Vial2Bag Advanced® Admixture 13mm and 20mm devices
The addition of the Vial2Bag Advanced® 13mm admixture device complements West's existing Vial2Bag Advanced® 20mm admixture device, with the two products providing options for the reconstitution and transfer of a drug using either a 13mm or 20mm vial and an IV bag before administration to the patient. The device is needle-free and has both a dual channel design to provide dedicated fluid pathways into and out of the IV bag and a robust vial spike design for connection to the drug vial.
"This year, West celebrates 100 years as an industry leader and scientific innovator in high-quality injectable solutions," said Cindy Reiss-Clark, Chief Commercial Officer at West. "The 13mm product is a key addition to our administration system portfolio, addressing the critical need for more drug preparation and delivery options at the point-of-care."
Vial2Bag Advanced® 13mm admixture device has been officially launched at Progressive Medical Inc's Booth #500 at the American Society of Health-System Pharmacists Midyear Clinical Meeting Dec. 3 through 7, in Anaheim, CA.
About
Vial2Bag Advanced® 13mm Admixture Device and Important Product and Safety Information
The Vial2Bag Advanced® 13mm admixture device is indicated to serve as a connection between a 50, 100 or 250ml IV bag, vial with 13mm closure, and an external IV administration set. The integrated vial adapter makes it possible to reconstitute and/or admix drugs prior to administration to the patient. The Vial2Bag Advanced® 13mm admixture device is indicated for adolescent and adult patients only. For more information visit page https://www.westpharma.com/products/vial-adapter-systems/vial2bag-advanced-admixture-adapter-drug-transfer-system.
The Vial2Bag Advanced® 13mm and 20mm admixture devices are 510(k) cleared by the United States Food and Drug Administration. Products are shown for INFORMATION purposes only and may not be approved for marketing in specific regions. Important product and safety information and warnings at: https://www.westpharma.com/products/vial-adapter-systems/vial2bag-advanced-admixture-adapter-drug-transfer-system. These products are for prescription use only. The Vial2Bag Advanced® 13mm and 20mm admixture devices are intended for U.S. healthcare professional use only.
About West
West Pharmaceutical Services, Inc. is a leading provider of innovative, high-quality injectable solutions and services. As a trusted partner to established and emerging drug developers, West helps ensure the safe, effective containment and delivery of life-saving and life-enhancing medicines for patients. With 10,000 team members across 50 sites worldwide, West helps support our customers by delivering approximately 47 billion components and devices each year.
2023 marks West's 100-year milestone of innovation and the critical role it continues to play in healthcare and the patient experience. Headquartered in Exton, Pennsylvania, West in its fiscal year 2022 generated $2.89 billion in net sales. West is traded on the New York Stock Exchange (NYSE: WST) and is included on the Standard & Poor's 500 index. For more information, visit www.westpharma.com.
West and the diamond logo are registered trademarks of West Pharmaceutical Services, Inc. in the United States and other jurisdictions.
Vial2Bag Advanced, Vial2Bag Advanced logo, Blue Vial Adapter, and Orange Vial Adapter are registered trademarks of West Pharma. Services IL, Ltd., a subsidiary of West Pharmaceutical Services, Inc.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Indications
-Targets
-Drugs
-Chat with Hiro
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.